d.planchard
@dplanchard
Thoracic Oncologist - Prof at University Paris Saclay - Head of Thoracic Group and CICT, Medical Oncology Dpt- Gustave Roussy - Villejuif - France 🇫🇷
ID:60281221
26-07-2009 10:42:09
1,9K Tweets
5,5K Followers
209 Following
Some advances for our BRAFV600E NSCLC patients… two standards in 2024 with Dabrafenib + Trametinib and Encorafenib + Binimetinib
review to read… npj Journals
rdcu.be/dE0vT
30 Posts Not To Miss From AACR 24 !
Dr. Kimryn Rathmell Lynn M. Schuchter, MD, FASCO @ASCO Vivek Subbiah, MD Dr. Patrick Hwu Wafik S. El-Deiry, MD, PhD, FACP Chendi Li d.planchard Harmony Saunders Paolo Tarantino AACR_CEO Jakob Nikolas Kather Nicholas Huntington Pashtoon Kasi MD, MS K Lukasik Christine Lovly, MD, PhD Ivy Riano, M.D. #OncoDaily
oncodaily.com/48590.html
It's great to see Gustave Roussy on the water in Brittany in the Golf du Morbihan, one of the most beautiful places in France! And the land of real sailors at the port of La Trinité... Gustave Roussy Gustave Roussy Alumni
Baseline (before tx) ctDNA level in #EGFR metastatic #NSCLC in FLAURA2 trial (osimertinib vs. osi + chemo) suggests - combo more beneficial when ctDNA detected. Potential strategy for tx adaptation? What about non-shedding tumors? #PasiJanne Dana-Farber #AACR24 EGFR Resisters
FLAURA2: On-treatment plasma EGFRm clearance prognostic but not predictive benefit with osimertinib + ChemoT vs Osi alone by P.Jänne at #AACR24 Gustave Roussy Dana Farber's EGFR-Mutant Lung Cancer Center Dana-Farber News EGFR Resisters
FLAURA2- Baseline detection of ctDNA may identify a subgroup of pts who derive most benefit from addition of chemoT to osimertinib as first line trtt for EGFRmut NSCLC by P.Jänne at #AACR24 EGFR Resisters Dana Farber's EGFR-Mutant Lung Cancer Center Gustave Roussy Dana-Farber News
Follow the post progression outcomes update of the controversial FLAURA2 Trial from the #ELCC24 conference. Key commentary from Jarushka Naidoo Balazs Halmos Stephen V Liu, MD d.planchard #lcsm
👉beta.kolpulse.com/public/1409290…
#ELCC24
Post progression outcomes in FLAURA2 (Ph III Osi+chemo v Osi):
- interim OS HR 0.75 p=0.028, trend (41% maturity)
- benefit in TTST/TTFT (time to next therapy)
Are these ‘relevant’ endpoints? Further data needed to establish as a new SOC #ESMOambassadors ESMO - Eur. Oncology
A fine review of the data and usefulness of MRD in clinical practice for both doctors and patients by Jordi Remon Gustave Roussy ! Predictive vs. prognostic? More work to do... #ELCC24 ESMO - Eur. Oncology IASLC